USP13 and metabolic dysfunction-associated steatotic liver disease: Therefore, inhibiting the TAK1 activation could reverse the exacerbation of NAFLD brought from the deficiency of USP13, indicating that targeting TAK1 is necessary for USP13 to alleviate NAFLD.